Segmed, Inc., the leader in real-world imaging data for research and AI development, announced the appointment of David Gascoigne as Chief Executive Officer. This leadership position marks a pivotal moment as the company accelerates its next phase of growth and innovation.
David brings more than 30 years of experience driving innovation and growth at the intersection of healthcare, life sciences, AI, and real-world data. A serial entrepreneur and proven operator, he has built and scaled businesses ranging from early-stage start-ups to global enterprises. Most recently, David served as CEO of Almaden Genomics, where he led the launch and commercialization of a cloud based, no-code genomics platform spun out of IBM Research. The software was the first no-code platform to accelerate genomic data analysis for researchers, bioinformaticians, and life science companies.
Also Read: QIAGEN boosts genomics with Genoox AI software buy
His prior executive roles include leadership positions at IQVIA where he was GM of Commercial Analytics, Symphony Health where he was EVP of Consulting, Analytics and Innovation, Sutherland Global Services where he was SVP of Healthcare Analytics, as well as serving as Chief Operating Officer at GNS Healthcare and a Partner in Digital Analytics at Accenture. David holds an advanced degree in Applied Statistics from the University of Sheffield in the U.K.
Throughout his career, David has consistently demonstrated the ability to transform complex real-world data assets into scalable, high-value solutions that drive measurable outcomes for life sciences, diagnostics, and healthcare organizations.
His appointment comes at a key moment for Segmed, as the company accelerates its expansion into new markets and advances its mission to power innovation in medical imaging, real-world data, and AI-driven healthcare solutions.
Source: PRNewswire
